HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Administration of recombinant human growth hormone normalizes GH-IGF1 axis and improves malnutrition-related disorders in patients with anorexia nervosa.

Abstract
High serum level of GH in the presence of low plasma level of insulin-like growth factor-I (IGF-I) is one of the endocrinological features of anorexia nervosa (AN). Whether the amount of endogenous GH is not enough to increase IGF-I is not certain. We studied the effect of recombinant human growth hormone (rhGH) on the GH-IGF-I axis and on malnutrition-related disorders in this syndrome. Twenty patients with AN were divided into two groups; one (N = 13) was given rhGH (0.33 mg/day), and the other (N = 7) was given placebo for 6 or 12 months, respectively. During each treatment, levels of serum GH, plasma IGF-I, serum thyroid hormones, serum cholesterol, fasting plasma glucose and cardiac function were monitored. Changes in body mass index (BMI) and calorie taken were also evaluated. Plasma IGF-I level increased from 74.4 +/- 41.9 to 269.0 +/- 31.2 microg/L (P<0.001) during administration of rhGH, which associated with a decrease in serum GH level from 17.0 +/- 15.0 to 1.6 +/- 0.8 microg/L (P<0.001). Administration of rhGH increased BMI, body temperature, fasting plasma glucose level, and food intake. Serum level of triiodothyronine, but not thyroxine, increased during treatment with rhGH. The treatment decreased serum levels of both total and HDL-cholesterol. Studies with echocardiography showed an increase in cardiac output during the treatment with rhGH. These improvements were not observed in patients treated with placebo. Administration of rhGH is recommended as one of the methods of managing the patients with AN.
AuthorsKiyoshi Hashizume, Satoru Suzuki, Ai Komatsu, Kunihide Hiramatsu, Jun-Ichiro Mori, Masanori Yamazaki, Teiji Takeda, Tomoko Kakizawa, Takahide Miyamoto, Yoichi Koizumi, Kazuo Ichikawa
JournalEndocrine journal (Endocr J) Vol. 54 Issue 2 Pg. 319-27 (Apr 2007) ISSN: 0918-8959 [Print] Japan
PMID17339748 (Publication Type: Controlled Clinical Trial, Journal Article, Retracted Publication)
Chemical References
  • Blood Glucose
  • Recombinant Proteins
  • Thyroid Hormones
  • Human Growth Hormone
  • Insulin-Like Growth Factor I
  • Cholesterol
Topics
  • Adult
  • Anorexia Nervosa (complications, psychology)
  • Attitude
  • Blood Glucose (metabolism)
  • Body Mass Index
  • Body Temperature (drug effects)
  • Cardiac Output (drug effects)
  • Cholesterol (blood)
  • Energy Intake (drug effects)
  • Female
  • Human Growth Hormone (administration & dosage, metabolism, therapeutic use)
  • Humans
  • Injections, Subcutaneous
  • Insulin-Like Growth Factor I (metabolism)
  • Malnutrition (drug therapy, etiology, metabolism, pathology)
  • Platelet Count
  • Recombinant Proteins (administration & dosage, therapeutic use)
  • Thyroid Hormones (blood)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: